Clinical Efficacy of 5-Aminolevulinic Acid Photodynamic Therapy Combined With Interferon Spray in Treating Common and Plantar Warts.

Photodermatol Photoimmunol PhotomedOct 7, 2026
Clinical ResearchDermatology

Sheng-Jiang Liang, Jia-Min Miao, Jie-Cheng Zheng et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the efficacy of 5-aminolevulinic acid photodynamic therapy (5-ALA-PDT) combined with recombinant human interferon alpha 2b (rhIFN-α2b) spray in 104 patients with refractory common and plantar warts. The intervention group showed a complete recovery rate of 90.20% compared to 62.26% in the control group (p = 0.002).

Key findings

  • The total effective rate was 96.08% in the intervention group versus 77.36% in the control group (p = 0.013).
  • Recurrence rates at 8 weeks were 2.17% in the intervention group compared to 24.24% in the control group.
  • At 6 months, recurrence rates were 4.35% in the intervention group versus 39.39% in the control group.

Why it matters

The study highlights a promising alternative treatment for common and plantar warts, particularly for patients with refractory cases, potentially improving patient outcomes and reducing recurrence rates.

Source

PubMed · PMID 42836509

Published in Photodermatol Photoimmunol Photomed. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.